Home » News » 02/06 » Allergan chief looks for new treatments

Allergan chief looks for new treatments

Date published: 09/02/2006

The head of Botox-maker Allergan has said that the company may be interested in buying up drugs designed to treat urology ailments and neurological conditions. Chief executive David Pyott told Reuters in an interview that urologists and neurologists would also grow to be important to the firm, as Botox could be allowed for use by migraine sufferers.

"We would be interested in anything used by neurologists, such as treatments for epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis and pain medication," he said. "And in urology, it could be drugs or devices for bladder and prostate problems."

Allergen is in the process of purchasing breast implant maker Inamed Corporation. On Monday the firm extended the deadline of its offer for the company to February 22nd, as it has yet to receive US antitrust approval for the move.

During the third quarter of 2005 Allergen generated $227.3 million in Botox sales, bringing its net earnings for the period to $122 million. As well as its use as an anti-wrinkle treatment, Botox has been approved for use in excessive sweating and for reducing eye blinking.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.